Manager TitleAgeSince
Chief Executive Officer - 21/03/2024
Director of Finance/CFO - 30/05/2024
Chief Tech/Sci/R&D Officer - 31/12/2014
Director TitleAgeSince
Director/Board Member - 31/12/2020
Director/Board Member - 21/03/2024
Director/Board Member - 30/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
+5.43%-10.33% - - 2.99M
+4.70%+0.21%+20.54%-31.54% 16.33B
+6.56%+7.83%-41.73%+54.18% 1.77B
-0.73%-2.78%-29.01%+17.73% 892M
+0.05%-0.11%+60.89%-2.02% 778M
-4.41%-20.55%-63.24%-85.97% 763M
-1.13%-7.14%-38.93%-51.20% 638M
-0.49%-8.37%-42.58%-55.29% 569M
-4.24%+1.93%-46.24%-41.77% 444M
+2.47%+1.63%+65.61%+56.76% 402M
Average +0.82%-3.91%-12.74%-15.46% 2.51B
Weighted average by Cap. +3.65%-0.36%+8.48%-23.48%
Logo NEOS AB
NeoDynamics AB (publ) is a Sweden-based company engaged in the medical industry. The Company focuses on developing and commercializing products for breast cancer screening, imaging, and breast cancer treatments. The Company’s product NeoNavia, enables a pulse biopsy system for ultrasound guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling tissue samples from both breasts and lymph nodes. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at clinics in United Kingdom, Germany, and Sweden.
Employees
13